Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
Eating smaller, frequent meals instead of three large meals also helps prevent overwhelming your digestive system
While no direct head-to-head trial exists, an indirect cross-trial review offers an interesting look at their differing mechanisms and clinical profiles
Limit saturated fat by limiting or reducing intake of fatty cuts of meat, egg yolks, and full-fat dairy
If you notice a significant decrease in exercise capacity, especially combined with a rapid heart rate, consider whether thyroid overmedication might be contributing
The added glucagon receptor activity is a key research distinction, not a reason to self-select one treatment over another
